-
公开(公告)号：US20240368564A1
公开(公告)日：2024-11-07
申请号：US18778386
申请日：2024-07-19
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor： Xin YU , Xavier de MOLLERAT du JEU , Chao Yan LIU , Jonathan ZMUDA , Jian LIU
Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
-
公开(公告)号：US20210054415A1
公开(公告)日：2021-02-25
申请号：US17093486
申请日：2020-11-09
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor： Xin YU , Xiquan LIANG , Xavier de MOLLERAT du JEU , Robert Jason POTTER
Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.
-
Patent Agency Ranking
公开(公告)号：US20180135077A1
公开(公告)日：2018-05-17
申请号：US15721105
申请日：2017-09-29
Applicant: Life Technologies Corporation
Inventor： Xin YU , Xavier de MOLLERAT du JEU
CPC classification number: C12N15/86 , C12N7/00 , C12N2740/15043 , C12N2740/15052 , C12N2740/16043 , C12N2740/16051
Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.
-
公开(公告)号：US20170107539A1
公开(公告)日：2017-04-20
申请号：US15294586
申请日：2016-10-14
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor： Xin YU , Xiquan LIANG , Xavier de MOLLERAT du JEU , Robert Jason POTTER
CPC classification number: C12N15/90 , A61K48/0033 , A61K48/005 , C12N9/22 , C12N15/88 , C12N2830/30 , C12Y301/00
Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.
-
公开(公告)号：US20230193214A1
公开(公告)日：2023-06-22
申请号：US18168396
申请日：2023-02-13
Applicant: Life Technologies Corporation
Inventor： Xin YU , Xavier de MOLLERAT du JEU , Chao Yan Lin , Jian Liu , Jonathan Zmuda
CPC classification number: C12N7/00 , C12N1/06 , C12N15/86 , C12N2750/14041 , C12N2750/14152
Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
-
公开(公告)号：US20200270583A1
公开(公告)日：2020-08-27
申请号：US16798193
申请日：2020-02-21
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor： Xin YU , Xavier de MOLLERAT du JEU , Chao Yan Liu , jJian Liu , Jonathan Zmuda
Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
-
公开(公告)号：US20220348964A1
公开(公告)日：2022-11-03
申请号：US17860833
申请日：2022-07-08
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor： Xin YU , Xavier de MOLLERAT du JEU
Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.
-
-
-
-
-
-
Search Results
7
records
(took 0.014 seconds)
